Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndro
3 hours ago
- #Cardiometabolic Multimorbidity
- #Atherogenic Index of Plasma
- #Cardiovascular-Kidney-Metabolic Syndrome
- Atherogenic index of plasma (AIP) and related modified indices are positively associated with the incidence and progression of cardiometabolic multimorbidity (CMM) in individuals with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3.
- In a prospective cohort study of 346,868 UK Biobank participants without baseline type 2 diabetes, coronary heart disease, or stroke, eight AIP-related indices showed hazard ratios from 1.12 to 1.37 per standard deviation increase for incident CMM over a median follow-up of 15.9 years.
- Multistate analyses indicated stage-specific associations during CMM progression, with stronger effects observed for transitions from baseline to type 2 diabetes and from single cardiometabolic disease to CMM involving coronary heart disease.
- Secondary analyses demonstrated that adding AIP-related indices to conventional risk factors improved prediction of CMM, with the AIP-body roundness index (AIP-BRI) providing the greatest incremental predictive value.
- Exploratory biomarker analyses suggested that inflammatory, liver, and renal biomarkers jointly accounted for 32.5-46.4% of the associations between AIP-related indices and CMM, though these findings are not causal.
- The study supports the potential utility of AIP-related indices for CMM risk stratification within the CKM framework, with AIP-BRI offering additional predictive information.